Invesco Ltd. Boosts Stock Holdings in Thermo Fisher Scientific Inc. $TMO

Invesco Ltd. lifted its stake in Thermo Fisher Scientific Inc. (NYSE:TMO) by 12.9% during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 2,163,261 shares of the medical research company’s stock after buying an additional 247,975 shares during the period. Invesco Ltd.’s holdings in Thermo Fisher Scientific were worth $1,253,501,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also bought and sold shares of the stock. High Note Wealth LLC boosted its stake in shares of Thermo Fisher Scientific by 170.6% during the fourth quarter. High Note Wealth LLC now owns 46 shares of the medical research company’s stock valued at $27,000 after purchasing an additional 29 shares during the period. Swiss RE Ltd. purchased a new position in shares of Thermo Fisher Scientific in the fourth quarter worth $28,000. JPL Wealth Management LLC bought a new stake in Thermo Fisher Scientific during the 3rd quarter valued at $28,000. Beacon Financial Strategies CORP purchased a new stake in Thermo Fisher Scientific during the 4th quarter valued at $29,000. Finally, Olistico Wealth LLC purchased a new position in shares of Thermo Fisher Scientific in the fourth quarter valued at about $29,000. 89.23% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

A number of analysts have recently weighed in on the stock. Royal Bank Of Canada set a $490.00 target price on shares of Thermo Fisher Scientific and gave the stock a “sector perform” rating in a report on Thursday, May 14th. Wells Fargo & Company cut their price objective on Thermo Fisher Scientific from $675.00 to $615.00 and set an “overweight” rating on the stock in a research report on Friday, May 8th. Barclays dropped their price target on Thermo Fisher Scientific from $650.00 to $625.00 and set an “overweight” rating for the company in a research note on Tuesday, April 14th. Robert W. Baird reduced their price objective on shares of Thermo Fisher Scientific from $653.00 to $639.00 and set an “outperform” rating on the stock in a research report on Friday, April 24th. Finally, Stifel Nicolaus dropped their target price on shares of Thermo Fisher Scientific from $700.00 to $600.00 and set a “buy” rating for the company in a research report on Friday, April 24th. Two investment analysts have rated the stock with a Strong Buy rating, eighteen have given a Buy rating and five have issued a Hold rating to the company. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $608.95.

Insider Buying and Selling at Thermo Fisher Scientific

In other news, COO Gianluca Pettiti sold 400 shares of Thermo Fisher Scientific stock in a transaction dated Monday, April 27th. The stock was sold at an average price of $462.66, for a total value of $185,064.00. Following the completion of the transaction, the chief operating officer owned 25,051 shares of the company’s stock, valued at $11,590,095.66. The trade was a 1.57% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 0.33% of the stock is owned by insiders.

Thermo Fisher Scientific Price Performance

Shares of TMO stock opened at $465.98 on Friday. The business’s fifty day moving average is $477.34 and its 200 day moving average is $523.72. The company has a quick ratio of 1.15, a current ratio of 1.53 and a debt-to-equity ratio of 0.77. The stock has a market cap of $173.17 billion, a price-to-earnings ratio of 25.62, a PEG ratio of 2.04 and a beta of 0.88. Thermo Fisher Scientific Inc. has a twelve month low of $390.50 and a twelve month high of $643.99.

Thermo Fisher Scientific (NYSE:TMO) last announced its earnings results on Thursday, April 23rd. The medical research company reported $5.44 EPS for the quarter, beating analysts’ consensus estimates of $5.25 by $0.19. The firm had revenue of $11.01 billion for the quarter, compared to analysts’ expectations of $10.86 billion. Thermo Fisher Scientific had a net margin of 15.15% and a return on equity of 16.86%. The company’s quarterly revenue was up 6.2% on a year-over-year basis. During the same quarter in the previous year, the business posted $5.15 EPS. Thermo Fisher Scientific has set its FY 2026 guidance at 24.640-25.120 EPS. Research analysts expect that Thermo Fisher Scientific Inc. will post 24.85 EPS for the current fiscal year.

Thermo Fisher Scientific Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, July 15th. Investors of record on Monday, June 15th will be given a dividend of $0.47 per share. This represents a $1.88 dividend on an annualized basis and a yield of 0.4%. The ex-dividend date of this dividend is Monday, June 15th. Thermo Fisher Scientific’s dividend payout ratio (DPR) is 10.34%.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific (NYSE: TMO) is a global provider of scientific instrumentation, reagents and consumables, software, and services that support research, clinical, and industrial laboratories. The company supplies analytical instruments and laboratory equipment, life sciences reagents and kits, specialty diagnostics, and a broad range of consumables used by researchers, clinicians, and manufacturers. Its offerings also include laboratory information management and data-analysis software, as well as service solutions such as instrument maintenance, validation, and logistics that help customers run complex workflows efficiently.

Thermo Fisher operates through multiple business areas that broadly cover life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services, including contract development and manufacturing for pharmaceutical and biotechnology companies.